Biotech | August 10, 2021
Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
Deal signed with AOP Orphan for US commercial rights
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The goal for the project is the identification and optimization of anti-viral compounds.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
The company expects revenue growth of 10-15 per cent in the US
Subscribe To Our Newsletter & Stay Updated
